Search all trials

Find therapies in clinical trials near you – page 10

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Breast cancer+1

Not recruiting

Registered drugNo placebo

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Everolimus

Contact Research Centre

Breast cancer+1

Not recruiting

Registered drug

Study of Tucatinib and Ado-Trastuzumab Emtansine for Patients with Advanced HER2+ Breast Cancer

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Tucatinib

Contact Research Centre

Breast cancer

Not recruiting

Registered drugNo placebo

Study of Abemaciclib and Giredestrant for Patients with Early Stage ER-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Abemaciclib

Contact Research Centre

Breast cancer+13

Not recruiting

InvestigationalNo placebo

Study of Fadraciclib in Adults with Advanced Solid Tumors (Including Breast, Colorectal, Endometrial, Ovarian, Biliary Tract, and Liver Cancer) and Lymphoma

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Fadraciclib

Contact Research Centre

Breast cancer+8

Not recruiting

InvestigationalNo placebo

Study of CYC140 oral medication for patients with advanced solid tumors and lymphoma

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cyc140 Monohydrochloride Monohydrate

Contact Research Centre

Breast cancer+10

Not recruiting

InvestigationalNo placebo

Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

InvestigationalNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Ibrutinib

Contact Research Centre

Breast cancer+7

Not recruiting

Registered drugNo placebo

Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Breast cancer

Not recruiting

Registered drugNo placebo

Study on the Effects of Chemotherapy and Endocrine Therapy in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer Using Tamoxifen and Anastrozole

Registered drugNo placebo

Ireland

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Breast cancer

Not recruiting

Registered drugNo placebo

Study on the Effects and Safety of Camizestrant (AZD9833) Compared to Fulvestrant in Postmenopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Camizestrant

Contact Research Centre

Breast cancer

Not recruiting

Registered drug

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Abemaciclib

Contact Research Centre

Breast cancer+5

Not recruiting

Registered drugNo placebo

Study of Nivolumab alone or combined with Ipilimumab for patients with advanced solid tumors (breast, gastric, pancreatic, lung, bladder, or ovarian cancer)

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Ipilimumab

Contact Research Centre

Breast cancer

Not recruiting

Registered drug

Study on Atorvastatin for Patients with Early Breast Cancer

Registered drug

Denmark

Participants:18–64 years · 65+ years
Substances:Atorvastatin

Contact Research Centre

Find therapies in clinical trials near you – page 10

168 trials match your criteria

Breast cancer+1

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Breast cancer+1

Study of Tucatinib and Ado-Trastuzumab Emtansine for Patients with Advanced HER2+ Breast Cancer

Breast cancer

Study of Abemaciclib and Giredestrant for Patients with Early Stage ER-Positive, HER2-Negative Breast Cancer

Breast cancer+13

Study of Fadraciclib in Adults with Advanced Solid Tumors (Including Breast, Colorectal, Endometrial, Ovarian, Biliary Tract, and Liver Cancer) and Lymphoma

Breast cancer+8

Study of CYC140 oral medication for patients with advanced solid tumors and lymphoma

Breast cancer+10

Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

Breast cancer+7

Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Breast cancer

Study on the Effects of Chemotherapy and Endocrine Therapy in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer Using Tamoxifen and Anastrozole

Breast cancer

Study on the Effects and Safety of Camizestrant (AZD9833) Compared to Fulvestrant in Postmenopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer

Breast cancer

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Breast cancer+5

Study of Nivolumab alone or combined with Ipilimumab for patients with advanced solid tumors (breast, gastric, pancreatic, lung, bladder, or ovarian cancer)

Breast cancer

Study on Atorvastatin for Patients with Early Breast Cancer

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.